Aayush Wellness reported a significant scale-up in financial performance for FY26, with consolidated revenue from operations more than doubling year-on-year. The company delivered strong top-line growth while maintaining profitability, reflecting successful execution of its preventive healthcare strategy.

Financial Performance

Consolidated revenue from operations stood at ₹15,548.15 lakh for the year ended March 31, 2026, up from ₹7,334.57 lakh in FY25. This represents a robust 112% year-on-year growth. Total income, which includes other income, rose to ₹15,809.17 lakh, an increase of 115% compared to the previous fiscal year.

Profitability metrics showed steady improvement alongside the revenue expansion. Profit before tax (PBT) increased to ₹440.35 lakh from ₹337.49 lakh in FY25. Net profit after tax (PAT) grew by 18% to ₹398.04 lakh, up from ₹336.58 lakh in the prior year.

Operational Highlights

The company continued to expand its integrated preventive healthcare ecosystem. Aayush Wellness launched several new nutraceutical products, including Liver Detox Tablets, Brain Fuel Capsules, and Immunity Booster Tablets. These launches targeted specific health concerns such as liver health, cognitive function, and general immunity.

The firm also strengthened its diagnostics vertical through Aayush Labs. It entered into a strategic collaboration with Healthrashi Nextgen India Limited for AI-enabled healthcare infrastructure. Additionally, the company partnered with Blinkit to enhance its omnichannel distribution network via quick commerce platforms.

Dividend and Governance

During FY26, the company paid an interim dividend of ₹0.025 per equity share. The Board of Directors proposed the reappointment of Mr. Gavadu Patil as a director and the appointment of M/s. A. Raghavendra Rao & Associates as statutory auditors for five years.

The Secretarial Audit Report noted a delay in filling the casual vacancy caused by the resignation of the previous statutory auditor, M/s. A J M S & Co. LLP. The Board appointed the new auditors in May 2026, after the prescribed 30-day period.

What the Numbers Show

The divergence between revenue growth and net profit expansion highlights the investment phase of the business. While revenue surged 112%, net profit grew only 18%. This compression in net margin—from approximately 4.6% in FY25 to 2.5% in FY26—indicates that operating expenses and marketing costs scaled faster than earnings during this period of rapid top-line expansion.

Mumbai, August 29, 2026 — Aayush Wellness launched Lung Care Tablets on August 29, 2026, entering the ₹18,913 crore respiratory healthcare market. The product targets smokers and individuals with respiratory issues.

The company disclosed the launch under Regulation 30 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015. Managing Director Naveenakumar Kunjaru stated the move aligns with the firm’s prevention-led vision, building on the success of Aayush Herbal Masala.

Market Context

India’s respiratory healthcare segment recorded sales of ₹18,912.64 crore in 2025, up from ₹17,199.40 crore in 2024. This represents approximately 10% year-on-year growth. The company noted that India accounts for 30.28% of global deaths from respiratory diseases.

Product Formulation

Lung Care Tablets combine herbal and nutritional ingredients, including N-Acetyl Cysteine (NAC), Vasaka Extract, Licorice, Quercetin, Vitamin C, Vitamin D2, and Zinc. The formulation aims to support:

• Respiratory wellness and lung function
• Healthy airway function
• Antioxidant and immune support
• Healthy inflammatory response
• Overall lung-health maintenance

What the Numbers Show

The 10% growth in the respiratory segment sales from ₹17,199.40 crore in 2024 to ₹18,912.64 crore in 2025 indicates consistent expansion in this therapeutic category. This growth trajectory supports the company’s strategic entry into a market where India holds a significant share of global disease burden.

Strategic Outlook

Aayush Wellness positions the new tablets as a daily wellness solution to complement its existing preventive-health products. The company aims to increase product depth and create cross-selling opportunities across its customer base by addressing rising health concerns with targeted solutions.